Surrozen, Inc. SRZN
Surrozen, Inc. (Nasdaq: SRZN) is an ophthalmology drug developer. Its lead program, SZN-8141, is in Pre-clinical for diabetic macular edema; neovascular AMD. Its next catalyst on record is SZN-8141: Initiation of Phase 1b/2a DUET study in DME (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SZN-8141 — Initiation of Phase 1b/2a DUET study in DME (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SZN-8141 | DME, wet AMD | antibody | Pre-clinical |
| SZN-8143 | DME, wet AMD, uveitic macular edema | antibody | Pre-clinical |
| Corneal endothelial and retinal degeneration research programs | corneal endothelial disease; photoreceptor degeneration | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.